Bacillus Calmette-Guerin

BIOLOGICAL4 trials

Sponsors

Bioniche Life Sciences Inc., University of Rome Tor Vergata, Pfizer, Mansoura University

Conditions

Bladder CancerNon-Muscle Invasive Bladder CancerNon-muscle Invasive Bladder Cancer

Phase 3

First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC

WithdrawnNCT01284205

Bioniche Life Sciences Inc.Bladder Cancer

Start: 2010-01-31End: 2017-02-28Updated: 2014-08-29

Sequential Bacillus Calmette-Guérin (BCG) and Electromotive Mitomycin-C Versus Bacillus Calmette-Guérin (BCG) Alone for High Risk Superficial Bladder Cancer

CompletedNCT01442519

University of Rome Tor VergataBladder Cancer

Start: 1994-01-31End: 2002-06-30Updated: 2011-09-28

A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer

Active, not recruitingNCT04165317

PfizerNon-muscle Invasive Bladder Cancer

Start: 2019-12-30End: 2026-12-02Updated: 2026-01-22

Unknown Phase

Machine Learning-Based Prediction of BCG Response in High-Risk Non-Muscle Invasive Bladder Cancer Patients

Mansoura UniversityNon-Muscle Invasive Bladder Cancer

Start: 2022-04-01End: 2023-12-01Target: 100Updated: 2022-04-18

Related Papers

The Evolving Landscape of Systemic Immunotherapy for Bacillus Calmette-Guérin-naïve High-risk Non-muscle-invasive Bladder Cancer: At the Edge of a Tsunami?

2025-08-051 citations

Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial

Nature Medicine2025-05-3130 citations

Sasanlimab in combination with bacillus Calmette-Guérin (BCG) in BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC): Event-free survival (EFS) subgroup analyses based on disease stage from the CREST study.

Journal of Clinical Oncology2025-05-281 citations

Sasanlimab in combination with bacillus Calmette-Guérin (BCG) in BCG-naive in BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC): Patient-reported outcomes (PROs) from CREST.

Journal of Clinical Oncology2025-05-28

A phase 3 study of the subcutaneous programmed cell death protein 1 inhibitor sasanlimab as single agent for patients with bacillus Calmette-Guérin, unresponsiv,e high-risk, non-muscle invasive bladder cancer: CREST Study Cohort B.

Journal of Clinical Oncology2022-06-013 citations

Is intravesical BCG alone still the only truly effective intravesical therapy for high risk non-muscle invasive bladder cancer?

Journal of Clinical Oncology2015-05-20